Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

PTSD Patients Sue over Colorado Marijuana Decision

By Pharmaceutical Processing | August 24, 2015

Colorado’s decision not to allow marijuana to treat post-traumatic stress disorder has prompted a lawsuit by PTSD sufferers. Five PTSD patients filed suit in Denver District Court. They’re challenging a July decision by the Colorado Board of Health not to make PTSD the first condition added to Colorado’s medical pot eligibility list in 15 years.

The PTSD rejection came despite a recommendation from Colorado’s chief medical officer and a panel of physicians. They said that questions remain about how effective pot is as a PTSD treatment, but that people with PTSD are commonly using pot anyway and that the designation would allow for better understanding about how people are using the drug. However, the Board of Health cited insufficient federal research and denied the request on a 6-2 vote.

A lawyer for the PTSD patients, Bob Hoban, said the board applied an improper standard in its rejection. “The board in effect established a standard that was impossible to meet,” Hoban said. “They insist on having a federal study, which in effect is a futile standard.”

Authorities have 21 days to respond to the complaint, which has no hearing date set. A spokeswoman for the Colorado Department of Public Health and Environment, which is also named in the lawsuit, declined to comment.

Colorado allows adults over 21 to buy pot for recreational use, with no doctor’s recommendation needed, but medical pot in Colorado is taxed at 2.9 percent, compared with at least 25 percent for recreational pot. Medical patients are also allowed to possess twice as much marijuana — two ounces instead of one.

Colorado had about 113,000 people on the medical marijuana registry in May, the most recent data available. Patients seeking medical marijuana must get a doctor’s recommendation to use it to treat one of eight debilitating conditions, including cancer, AIDS, chronic wasting diseases, glaucoma, seizures, persistent muscle spasms, severe pain and severe nausea. More than 93 percent of current patients list severe pain as their condition.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE